S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

Castle Biosciences Stock Forecast, Price & News

-1.52 (-2.33 %)
(As of 10/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume143,489 shs
Average Volume242,035 shs
Market Capitalization$1.60 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CSTL News and Ratings via Email

Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Castle Biosciences logo

About Castle Biosciences

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.


See More Headlines

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$62.65 million
Book Value
$20.62 per share


Net Income
$-10.28 million




Market Cap
$1.60 billion
Next Earnings Date
11/8/2021 (Estimated)
Not Optionable


Overall MarketRank

2.64 out of 5 stars

Medical Sector

66th out of 1,361 stocks

Medical Laboratories Industry

4th out of 30 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -

Castle Biosciences (NASDAQ:CSTL) Frequently Asked Questions

Is Castle Biosciences a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Castle Biosciences stock.
View analyst ratings for Castle Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Castle Biosciences?

Wall Street analysts have given Castle Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Castle Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Castle Biosciences' next earnings date?

Castle Biosciences is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Castle Biosciences

How were Castle Biosciences' earnings last quarter?

Castle Biosciences, Inc. (NASDAQ:CSTL) announced its quarterly earnings results on Sunday, August, 8th. The company reported ($0.34) EPS for the quarter, missing the Zacks' consensus estimate of ($0.29) by $0.05. The business had revenue of $22.76 million for the quarter, compared to analysts' expectations of $19.09 million. Castle Biosciences had a negative trailing twelve-month return on equity of 5.90% and a negative net margin of 28.88%.
View Castle Biosciences' earnings history

How has Castle Biosciences' stock been impacted by Coronavirus (COVID-19)?

Castle Biosciences' stock was trading at $28.97 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CSTL shares have increased by 119.5% and is now trading at $63.58.
View which stocks have been most impacted by COVID-19

What guidance has Castle Biosciences issued on next quarter's earnings?

Castle Biosciences updated its FY 2021 earnings guidance on Monday, September, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $89 million-$93 million, compared to the consensus revenue estimate of $83.64 million.

What price target have analysts set for CSTL?

6 analysts have issued twelve-month target prices for Castle Biosciences' stock. Their forecasts range from $52.00 to $94.00. On average, they expect Castle Biosciences' stock price to reach $79.83 in the next year. This suggests a possible upside of 25.6% from the stock's current price.
View analysts' price targets for Castle Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Castle Biosciences' key executives?

Castle Biosciences' management team includes the following people:

What other stocks do shareholders of Castle Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Square (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC).

When did Castle Biosciences IPO?

(CSTL) raised $50 million in an initial public offering on Thursday, July 25th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. SVB Leerink and Baird served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

What is Castle Biosciences' stock symbol?

Castle Biosciences trades on the NASDAQ under the ticker symbol "CSTL."

Who are Castle Biosciences' major shareholders?

Castle Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Level Four Advisory Services LLC (0.02%), NEXT Financial Group Inc (0.01%), Harbor Investment Advisory LLC (0.00%) and Creative Financial Designs Inc. ADV (0.00%). Company insiders that own Castle Biosciences stock include Adam Jay Sussman, Bernhard E Spiess, Bernhard E Spiess, Bonnie H Anderson, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Frank Stokes, Jeffrey E Eberwein, Joseph C Cook III, Kristen M Oelschlager, Mara G Aspinall, Sofinnova Healthquest Partners and Tobin W Juvenal.
View institutional ownership trends for Castle Biosciences

Which major investors are selling Castle Biosciences stock?

CSTL stock was sold by a variety of institutional investors in the last quarter, including Creative Financial Designs Inc. ADV. Company insiders that have sold Castle Biosciences company stock in the last year include Adam Jay Sussman, Bernhard E Spiess, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Frank Stokes, Joseph C Cook III, Kristen M Oelschlager, and Tobin W Juvenal.
View insider buying and selling activity for Castle Biosciences
or view top insider-selling stocks.

Which major investors are buying Castle Biosciences stock?

CSTL stock was purchased by a variety of institutional investors in the last quarter, including Level Four Advisory Services LLC, NEXT Financial Group Inc, and Harbor Investment Advisory LLC.
View insider buying and selling activity for Castle Biosciences
or or view top insider-buying stocks.

How do I buy shares of Castle Biosciences?

Shares of CSTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Castle Biosciences' stock price today?

One share of CSTL stock can currently be purchased for approximately $63.58.

How much money does Castle Biosciences make?

Castle Biosciences has a market capitalization of $1.60 billion and generates $62.65 million in revenue each year. The company earns $-10.28 million in net income (profit) each year or ($0.47) on an earnings per share basis.

How many employees does Castle Biosciences have?

Castle Biosciences employs 200 workers across the globe.

What is Castle Biosciences' official website?

The official website for Castle Biosciences is castlebiosciences.com.

Where are Castle Biosciences' headquarters?

Castle Biosciences is headquartered at 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546.

How can I contact Castle Biosciences?

Castle Biosciences' mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The company can be reached via phone at (866) 788-9007 or via email at [email protected].

This page was last updated on 10/16/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.